Impact of COVID-19 Disease in Early Breast Cancer Management: A Summary of the Current Evidence.

Purpose: An expert panel on breast cancer and COVID-19 disease was convened to address the impact of the COVID-19 pandemic for early breast cancer (eBC) management.
Methods: To ensure that the most clinically relevant information was addressed, essential information was drawn from several of the latest national and international guidelines and another technical document. The expert panel met in five virtual closed sessions from November 2020 to May 2021 to consult on the relevant data from evidence-based results. The data gathered were discussed on an online platform.
Results: This article reports the expert panel's highlights of these meetings' discussions. In addition, it provides practical recommendations covering topics regarding diagnosis, treatment, and management of patients with eBC in clinical settings routinely encountered by health care professionals amid the COVID-19 pandemic.
Conclusion: This article provided guidance on several topics regarding eBC management amid the COVID-19 pandemics to inform safer care practices.
Competing Interests: Francisco Pimentel CavalcanteConsulting or Advisory Role: Pfizer, Roche, MSD OncologySpeakers' Bureau: Roche, Pfizer, Gencell Pharma, LibbsTravel, Accommodations, Expenses: Roche, Gencell Pharma Carlos Eduardo dos Santos FerreiraSpeakers' Bureau: Roche Diagnostica Brasil, Beckman Coulter, Abbott Diagnostics Gilberto AmorimStock and Other Ownership Interests: Pfizer, AstraZenecaHonoraria: Roche, Novartis, Lilly, Sanofi/Aventis, Pfizer, MSD OncologyConsulting or Advisory Role: Novartis, Roche, MSD OncologyTravel, Accommodations, Expenses: Roche, Novartis Luciana LandeiroConsulting or Advisory Role: GlaxoSmithKline Álvaro Pulchinelli JrConsulting or Advisory Role: Roche, Thermo Fisher Scientific, bioMerieux, BD Biosciences Daniela Dornelles RosaConsulting or Advisory Role: Roche, Novartis, AstraZeneca, Lilly, GlaxoSmithKline, Sanofi, Libbs, Pfizer, Amgen, Zodiac PharmaSpeakers' Bureau: Novartis, Lilly, PfizerTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported.